Skip to main content
BMJ Open logoLink to BMJ Open
. 2016 Feb 8;6(2):e009889. doi: 10.1136/bmjopen-2015-009889

Bibliometric analysis of the top-cited gastroenterology and hepatology articles

Samy A Azer 1, Sarah Azer 2
PMCID: PMC4746458  PMID: 26857105

Abstract

Objective

To identify the top-cited articles in gastroenterology and hepatology, and analyse their characteristics.

Methods

Two searches were conducted in the Science Citation Index Expanded database; a search of 69 journals under the category ‘Gastroenterology and Hepatology’ (list A) and a keyword search of all journals (list B). The search results were analysed and the inter-rater coefficient of agreement between evaluators was measured using Cohen κ.

Results

The number of citations varied from 1049 to 2959 in list A and from 1929 to 5500 in list B. In both lists, the majority of articles were research papers. No significant correlations were found between the number of citations and the number of years since publication (R2=0.00992, p=0.473 and R2=0.00202, p=0.757, respectively). However, the mean number of citations of papers published before the year 2000 was lower than those published after 2000 (36.70±19.31 vs 106.03±39.22). No correlation was found between number of authors and the number of citations (R2=0.04352, p=0.130), but strong correlations were found between the number of institutes involved or number of countries and the number of citations (R2=0.275, p<0.001 and R2=0.16181, p=0.003, respectively). Females were under-represented in authorship (45 vs 254, p=0.004). Only 21 papers (of 54) in list A were supported by grants. No correlation was found between number of grants received and the number of citations (R2=0.02573, p=0.247). The inter-rater agreement between evaluators had a Cohen κ coefficient 0.76–0.84.

Conclusions

Top-cited articles were not only published in highly ranked journals specialising in Gastroenterology and Hepatology but also in 14 journals not specialised in this field. The number of citations correlated with the number of institutes and the number of countries involved but not with the number of grants received or the number of authors. Females were under-represented in the authorship.

Keywords: MEDICAL EDUCATION & TRAINING


Strengths and limitations of this study.

  • Two searches were conducted in the Science Citation Index Expanded database.

  • The search was based on journals with high impact factor and only those in the English language.

  • Analysis explored a range of parameters in the assessment.

Introduction

While the number of citations alone cannot reveal why a paper is considered important enough to attract citations by other researchers1 nor reflect fully the quality of a paper,2 the citations received by scientific publications have been used as a proxy measurement to assess the work of researchers and impact of research,3 and to rank researchers on the basis of differences in citation indices.3 4 Recently, Nicholson and Ioannidis5 explored whether there is a link between highly cited research and US National Institute of Health (NIH) funding. Their findings showed that too many US authors of the most innovative and influential papers in the life sciences do not receive NIH funding.5 While these findings raise a number of possibilities, there is ongoing debate on the importance of citations received by scientific publications.6 For example, using citation metrics to appraise scientists and their work has many pitfalls,7 yet the numbers of published research papers and their citations have been used as a measure to assess the quality of research on national scales and to set it in an international context.8 This may explain why top-cited publications are usually seen by researchers and universities as influential papers, and can be used in measuring the impact of the work of other researchers.9

The reputation of scientists and the influence of their work in a particular discipline can therefore be proportionally related to the number of citations received by their publications.3 This is particularly important when there is a pattern of consistency and progressive input into their discipline over time, as demonstrated from their publications’ record and the citation history of their publications. The more influential their papers, the more they are making an impact, not only in their institutes or at a national level, but at a global level as well.5

The identification of top-cited articles in gastroenterology and hepatology is useful for a number of reasons. First, the search identifies the articles that have contributed to the different topics related to the discipline. Furthermore, the top-cited articles enable readers to know authors who and institutions that have contributed to such work. Garfield and Welljams-Dorof10 showed that a simple, quantitative and objective algorithm based on citation data of high-impact research authors, can effectively corroborate and even help in predicting Nobel Prize award winners. Finally, the lists present useful information to authors and researchers regarding top-cited articles that can be used in teaching and learning of undergraduate and postgraduate students.11

Top-cited papers have been recently studied in several fields, including cardiovascular medicine,11 cardiac surgery,12 arthroscopic orthopaedic surgery,13 respiratory system,14 dermatology15 and medical education.16 An abstract on the top-cited articles in gastroenterology and hepatology was presented at Asia-Pacific Digestive Week in 2009.17 The objectives of this study are to identify the 50 top-cited articles in gastroenterology and hepatology, and to analyse their characteristics.

Methods

Study design

The Science Citation Index Expanded (SCI-Expanded) database of the Thomson Reuters Web of Science was used for citation tracking and the identification of most-cited articles. Although Scopus and Google scholar also provide citation tracking, it was decided to limit the search to the SCI-Expanded database. This is because the SCI-Expanded database is regularly updated and its 2014 Journal Citation Reports (JCRs) included 76 journals in the field of Gastroenterology and Hepatology. Google Scholar was not used because it is difficult to search and its citations include textbooks, monographs, conference proceedings, as well as non-peer-reviewed work.18 The Scopus database was not searched because it is not extensive in its coverage and its records only go back to 1966.19

To maximise the outcomes of this study, two search strategies were used. The first aimed at searching journals listed in the JCR 2014 under the category ‘Gastroenterology and Hepatology’. The second search aimed at identifying most frequently cited articles in all the database including journals not dedicated to gastroenterology and hepatology, such as general medicine, internal medicine and general surgery journals, as well as biology and related disciplines.

Searching the gastroenterology and hepatology journals

On 27 May 2015, the two authors (a professor of medical education as well as gastroenterology consultant, and a senior surgical registrar) along with a research assistant with a background in medicine, searched the SCI-Expanded database to retrieve top-cited articles. This search was conducted via the JCR 2014 under the category ‘Gastroenterology and Hepatology’. The category comprised 76 journals at the time of conducting the search. Seven journals were not searched because they were in languages other than English. Journals not in the English language were excluded because neither of the authors of this work are competent in the Spanish, Italian or German languages. Also, there are articles on the topic covering top-cited articles in languages other than English.20 Interestingly, after identifying the list of top-cited articles, and again checking these seven non-English journals, none had a paper with a citation higher than the paper ranked number 50 in the list.

A list identifying the 50 top-cited articles was reviewed again and checked regarding authorship, title of the article, number of citations and the institution of the first author (list A, see appendix 1). Articles that shared the same number of citations were given the same rank number.

Searching the Web of Science using keywords

The second search was conducted on 27 May 2015. The aim of the second search was to identify top-cited articles published in journals not dedicated to the field. The SCI-Expanded database was searched using the following keywords: ‘Bilirubin’, ‘Biliary disease’, ‘Esophageal disorder’, ‘Esophageal reflux disease’, ‘Esophageal cancer’, ‘Peptic ulcer disease’, ‘Helicobacter pylori’, ‘Gastric ulcer’, ‘Gastritis’, ‘Gastric cancer’, ‘Pancreatitis’, ‘Pancreatic cancer’, ‘Jaundice’, ‘Malabsorption’, ‘Celiac disease’, ‘Irritable bowel syndrome’, ‘Inflammatory bowel disease’, ‘Ulcerative colitis’, ‘Crohn's disease’, ‘Colitis’, ‘Diarrhea’, ‘Constipation’, ‘Esophageal varices’, ‘Chronic hepatitis’, ‘Viral hepatitis’, ‘Cirrhosis’, ‘Ascites’, ‘Chronic liver disease’, ‘Liver cell failure’, ‘End-stage liver disease’, ‘Gastrointestinal bleeding’, ‘Colon cancer’, ‘Diverticular disease’, ‘Liver function’, ‘Gallbladder disease’, ‘Gallstones’, ‘Cholecystitis’, ‘Medications and gastrointestinal diseases’, ‘Vomiting’, ‘Abdominal pain’, ‘Liver transplantation’; and ‘Gastrointestinal endoscopy’, ‘Gastrointestinal disease’, ‘gastrointestinal motility’, ‘Liver disease’.

These keywords were identified using the terminology used by major journals in gastroenterology and hepatology, and the major conference proceedings in the field such as the American Gastroenterological Association Annual Scientific Meeting, the American College of Gastroenterology Annual Scientific Meeting, the United European Gastroenterology Week, the Canadian Digestive Diseases Week, World Gastroenterology Congress and the American Association for the Study of Liver Diseases Annual Meeting.

Inclusion and exclusion criteria

Papers focusing on gastroenterology or hepatology as the main topic and in the English language were included. The exclusion criteria were: (1) articles in languages other than English, (2) articles focused on broad areas without giving the whole emphasis to gastroenterology or hepatology knowledge.

Assessing the articles

Following the methods of Lefaivre et al,21 each paper in the top 50 most cited articles list was reviewed. The full text of the articles included in lists A and B was obtained and a copy given to each evaluator. The following information was analysed: (1) the authors’ names and affiliations, (2) the city and country of publication, (3) the number of citations and (4) the year of publication and the calculation of the number of years since publication.

It was decided not to use the Web of Science classification because we noted that papers identified by the publishing journals as original research, article or practical guidelines were all grouped by the Web of Science and identified under the category ‘article’ or ‘review’. For consistency and for the purposes of this research, a definition of the category ‘review paper’, ‘article’, ‘educational guide’ and ‘research’ has been given in the glossary (box 1). Also, the type of research used in the top-cited papers has been placed under the following types: cross-sectional, case–control, cohort study, randomised controlled trial, experimental study and causal-comparative study. A definition of each type has been given in the glossary (box 1). The two authors independently ranked each paper identified with regard to paper category and research type for research papers. Articles that covered more than one topic were classified on the basis of the aim of the study and the main outcome. These articles were discussed among the researchers until a final topic was identified.

Box 1. Glossary.

Articles: Reports with conclusions that represent a substantial advance in the understanding of an important topic or problem. They provoke thoughts and ideas, and they aim at establishing new directions.

Case–control studies: In these studies, patients who developed a disease are compared with controls or referents groups (with no disease). The studies aim at estimating ORs or changes caused by the disease. The researchers have to identify potential confounding factors by making appropriate adjustment in the design of the study and in the analysis. This may be achieved either by matching cases and controls for exposure to confounders on an individual basis (by pairing each case with a control of same age and sex) or group comparison basis (controls have overall age and sex distribution similar to the patients).

Causal-comparative studies: These studies attempt to identify cause–effect relationships. The approach involves starting with an effect and seeking possible causes. The design involves comparison.

Cohort studies: In these studies, a group of individuals is followed over a period of time to assess the individuals’ health outcomes. In these studies, individuals who do not have the outcome of interest initially are identified and grouped in subsets that differ in their exposure to a particular factor, for example, hepatitis C infection, and non-exposure. The follow-up of the two groups over time enables the comparison of health outcomes. The cohort could be grouped according to whether they had or had not been exposed and the analysis of health outcomes could compare the frequency (the incidence) of a particular change (eg, liver cirrhosis) between the groups. Cohort studies could be prospective cohort studies or retrospective cohort studies.

Cross-sectional studies: These studies measure, in a population, at a point in time, the prevalence of health outcomes or determinants of health or both. They can also be used in planning healthcare. Cross-sectional studies are best suited to study aetiology of diseases that produce little disability in a population or the early phase of more serious diseases. However, the results of cross-sectional surveys (design) that explore aetiology have to be interpreted with great caution, as the findings identified may be associated changes rather than the causes of the change or the condition.

Experimental studies: In these studies, researchers are in control of the research design by determining the groups to be exposed and the groups not to be exposed. However, deliberate exposure of participants to potentially serious hazards does not follow the World Medical Association's Declaration of Helsinki, will not be approved by a formally constituted research ethics committee and may form a constraint on such research. In animal work, experimental study design may be in vivo or in vitro studies.

Practical guidelines: Resources usually written by a team of experts in the area/topic, and aimed at providing clinicians and researchers with a resource on principles, current evidence, applications and regulations.

Randomised controlled trials: Aim at evaluating therapeutic intervention by using experimental design and randomisation of participants. Participants are selected on the basis of inclusion criteria; those satisfying the entry criteria and representing the target population are asked to consent to participation. Participants are randomised to the intervention (treatment) under comparison using a valid randomisation method, usually conducted by a third party, such as web-based or phone-based randomisation. The use of randomisation means eventual distribution of any confounding factors and prognostic markers between the different treatment groups.

Reviews: Articles reviewing progress of knowledge in a particular topic, critically analysing the current status of the literature and presenting an understanding of the topic by discussing related literature, and identifying gaps in knowledge and highlighting future directions for further research.

Research papers: Original studies making systematic investigations into a problem, using valid and reliable methods in order to establish answers to the research questions made, and come with conclusions. Research methods used may be qualitative, quantitative or mixed methods.

The number of authors for each publication and the representation of females in the authorship of top-cited articles were identified. Collaboration type was determined by the addresses of the authors, and the term ‘country independent work’ was assigned if the researchers’ addresses were from the same country. Articles that were the result of collaborative work from more than one country were identified.22 Those from the same country were classified into those from one institute and those from more than one institute.23 Papers that received grant support were also identified.

Evaluating the journals

The journals in which the top 50 articles were published were evaluated with respect to the following: (1) the Impact Factor of each journal, determined as reported in the JCR 2014 and (2) the ranking of the article, at the time of the research, in comparison to other articles published in that journal on the basis of the number of citations obtained. For example, an article ranked number 1 in the journal it was published in means that the article received the highest number of citations in comparison to all other articles published in that journal. The aim of this evaluation was to assess the position of articles identified among the 50 top-cited articles in regard to their ranking among other articles published in their respective journals. Such assessment will give a better idea about the significance of the articles included in list B among other topics published in journals not dedicated to the field.

Statistical analysis

Using SPSS software (IBM SPSS Statistics Premium V.22.0 for Mac OS-SPSS Inc, Chicago, Illinois, USA), the data were analysed and reported as total and percentage. Pearson's correlation coefficient (r) was calculated to determine if the number of years since publication was correlated to the number of citations obtained. Also, the correlations between the number of authors, the number of institutes or the number of countries involved or the number of grants received against the number of citations were calculated. The degree of agreement between evaluators was calculated using Cohen κ index for inter-rater coefficient.24

Results

Top-cited papers identified by searching journals (list A)

Appendix 1 summarises the characteristics of top-cited articles published in the gastroenterology and hepatology journals (list A).25–78 Articles are listed in descending order from 1 to 50, with the highest absolute citation number ranked 1 and the article with the lowest citation ranked 50, as on the day of the search. Articles with the same number of citations were given the same rank number. Four articles49 56 64 78 had the same number of citations and were given the same ranks. Therefore, the total number of articles in list A is 54, and not 50. The denominator used in calculating the percentages is 54. All articles were published in the English language (list A).

Table 1 shows that these articles were published over a 66-year period (from 1945 to 2011). During the period from 1945 to 1987, only seven articles (12.9%) were included. However, the number increased progressively from 1988 to 2011, making a total of 47 (87%) articles.

Table 1.

Top-cited articles in Gastroenterology and Hepatology, identified by searching gastroenterology and hepatology journals (list A): by article type and year of publication*

Article type Year of publication: number of articles (references)
1945–1975 1976–1981 1982–1987 1988–1993 1994–1999 2000–2005 2006–2011 Total (%)
Article 174 249 53 227 35 128 6 (11.1)
Review 143 431 38 46 63 552 64 67 75 76 232 77 12 (22.2)
Practical Guidelines 247 55 325 50 59 739–41 44 66 69 70 12 (22.2)
Research 145 426 29 37 65 161 551 56 60 68 71 433 36 42 57 830 34 48 58 62 72 73 78 154 24 (44.4)
Total (%) 1 (1.8) 5 (9.2) 1 (1.8) 8 (14.8) 12 (22.2) 17 (31.5) 10 (18.5) 54 (100)

*The search was conducted on 27 May 2015. The total number of articles included in list A is 54, and not 50, because 4 articles had the same number of citations. Articles with reference numbers25–33 appeared in lists A and B, but with different rankings.

Table 2 summarises the distribution of gastroenterology and hepatology topics in relation to the four categories. The majority of the top-cited articles were research papers (n=24, 44.4%), the remaining were practical guidelines (n=12, 22.2%) and reviews (n=12, 22.2%). Only six were articles (11.1%). The topics can be summarised as follows: chronic hepatitis and viral hepatitis (n=12, 22.2%), hepatocellular carcinoma (n=9, 16.7%), inflammatory bowel disease (n=7, 12.9%), colorectal cancer (n=7, 12.9%), fatty liver disease (n=6, 11.1%), gastro-oesophageal reflux disease (n=2, 3.7%), gastric ulcer and H. pylori (n=2, 3.7%), prostaglandins and gastric protection (n=2, 3.7%), and end-stage liver disease and liver failure (n=2, 3.7%). The remaining topics are shown in table 2.

Table 2.

Top-cited articles in Gastroenterology and Hepatology, identified by searching gastroenterology and hepatology journals (list A): by article topic and category*

Topic† Category: number of articles (references)
Article Review Practical guidelines Research Total (%)
Gastro-oesophageal reflux disease 169 157 2 (3.7)
Gastric ulcer, Helicobacter pylori 170 145 2 (3.7)
Prostaglandins and gastric protection 174 137 2 (3.7)
Functional bowel disease 140 156 2 (3.7)
Coeliac disease 153 1 (1.8)
Intestinal ischaemia 165 1 (1.8)
Inflammatory bowel disease 346 67 77 429 60 61 68 7 (12.9)
Colorectal cancer 149 175 347 50 55 233 51 7 (12.9)
Chronic hepatitis and viral hepatitis 127 231 64 441 44 59 66 526 36 58 73 78 12 (22.2)
Fatty liver disease 135 138 430 42 48 62 6 (11.1)
End-stage liver disease and liver failure 234 71 2 (3.7)
Hepatocellular carcinoma 128 432 52 76 63 225 39 254 72 9 (16.7)
Endoscopic sphincterotomy 133 1 (1.8)
Total (%) 6 (11.1) 12 (22.2) 12 (22.2) 24 (44.4) 54 (100)

*The search was conducted on 27 May 2015. The total number of articles included in list A is 54, and not 50, because 4 articles had the same number of citations. Articles with reference numbers25–33 appeared in lists A and B but with different rankings.

†Some studies covered more than one topic, and were classified depending on the aim of the study and the main outcomes.

The articles were published in the following journals: Gastroenterology (n=26, 48%), Hepatology (n=17, 31.4%), Journal of Hepatology (n=2, 3.7%), American Journal of Gastroenterology (n=2, 3.7%), Gut (n=2, 3.7%), Seminars in Liver Disease (n=1, 1.8%), Gastrointestinal Endoscopy (n=1, 1.8%), Diseases of Colon & Rectum (n=1, 1.8%), Digestive Diseases and Sciences (n=1, 1.8%) and Journal of Viral Hepatitis (n=1,1.8%) (see online supplementary appendix 1).

The most frequently cited article, by Bruix and Sherman (2005), was cited 2959 times over 10 years.25 Two articles were ranked number 50; an article by Baggio and Drucker77 was cited 1049 times over 8 years, and an article by Bedossa et al78 cited 1049 times over 12 years. No correlation was found between the number of citations of these papers and the number of years since publication (R2=0.00992, p=0.473) (figure 1A). However, the mean number of citations of papers published before 2000 was lower than those published after 2000 (36.70±19.31 vs 106.03±39.22) (figure 1B, C).

Figure 1.

Figure 1

(A) Top-cited gastroenterology and hepatology articles identified by searching journals (list A): correlation between the number of citations and the number of years since publication, (B) Number of citations of papers published before the year 2000 (mean±SD), (C) Number of citations of papers published after the year 2000 (mean±SD), (D) Top-cited gastroenterology and hepatology articles identified by searching journals (list A): correlation between the number of citations and the number of institutions involved, (E) Top-cited gastroenterology and hepatology articles identified by searching journals (list A): correlation between the number of citations and the number of countries, (F) Top-cited gastroenterology and hepatology articles identified by searching journals (list A): correlation between the number of citations and the number of authors, and (G) Top-cited gastroenterology and hepatology articles identified by searching journals (list B): correlation between the number of citations and the number of years since publication.

Figure 1.

Figure 1

Continued.

A strong correlation was found between the number of institutes involved (figure 1D) (R2=0.27531, p<0.001) or the number of countries, and the number of citations received (R2=0.16181, p=0.003) (figure 1E). Table 3 shows further analysis of top-cited articles in list A in regard to authorship, institutes involved, countries and grants received. No correlation was found between the number of authors of top-cited articles and the number of citations (R2=0.0452, p=0.130) (figure 1F).

Table 3.

Further analysis of the 50 top-cited papers on gastroenterology and hepatology*

Variable Number Median IQR Mean±SD p Value
Number of authors
 Males 254 4 4 4.70±3.27 0.004
 Females 45 1 1 2.04±2.01
Institutes involved
 1 26 1 0 1.00±0.00 <0.001
 2–3 16 2 0.25 2.25±0.44
 >3 12 7.75 4.75 7.75±4.26
Countries
 1 44 1 0 1.00±0.00 <0.001
 2–3 4 2 0.25 2.25±0.50
 > 3 6 4.5 4.0 6.00±2.75
Grant support†
 Yes 21‡ 0 2 0.85±1.20
 No 33 0 0.0 0

*The analysis comprises 54 top-cited articles (list A).

†Some projects received grants from more than one body.

‡Only 10 top-cited articles published after the year 2000 were supported by grants.

Most articles originated from the USA (n=31, 57.4%), Spain (n=6, 11.1%), the UK (n=4, 7.4%), France (n=3, 5.5%), Canada (n=2, 3.7%), the Netherlands (n=2, 3.7%), Belgium, Italy, Japan, Germany, Switzerland and China (Hong Kong) (n=1, 1.8%) for each country.

Careful assessment of the authorship of top-cited articles shows that some authors contributed to more than one article in the list. Bruix was the first author of three articles,25 28 39 and was the second and third author of two other articles.52 63 In his pioneering work, the author focused on the clinical management of hepatocellular carcinoma25 28 39 52 and prognosis of hepatocellular carcinoma.63 Llovet co-authored three articles with Bruix.28 52 63 Also, Sherman co-authored three articles with Bruix.25 28 39 Lok was the first author of two articles44 66 and co-authored one article.58 These articles were on chronic hepatitis B,44 66 and assessment of a simple non-invasive index for predicting fibrosis and cirrhosis in patients with chronic hepatitis C.58 Ishak was the first author of one article27 and co-authored another article.26 These articles were on histological grading and staging of chronic hepatitis,27 and the use of a numerical scoring system for assessing histological activity in patients with asymptomatic chronic active hepatitis.26 Desmet was the first author of one article31 and co-authored another article with Ishak.27 Bedossa was the first author of two articles.36 78 These articles were on an algorithm for the grading of activity in chronic hepatitis C36 and sample variability of liver fibrosis in chronic hepatitis C.78 McCullough was a co-author of two articles.30 42 Both articles were on non-alcoholic fatty liver disease. Strader was the first author of one article59 and a co-author of another article,41 both articles were on management of hepatitis C. Winawer was the first author of two articles.47 50 These articles were on colorectal cancer. Fletcher co-authored with Winawer on two articles.47 50 No correlation was found between the number of grants received and the number of citations received (R2=0.0257, p=0.247).

Top-cited articles identified by keyword search (list B)

Online supplementary appendix 2 summarises the top-cited articles on gastroenterology or hepatology identified by searching the Web of Science across all journals (list B).25 33 79–119 Articles are listed in descending order by rank from 1 to 50 based on the absolute number of citations received as of the day of the search.

Table 4 shows that these articles were published over a 35-year period (from 1973 to 2008). During the period from 1973 to 1987, only six articles (12%) were published. However, the number increased progressively over the years from 1988 to 2008, making a total of 44 (88%) articles. Table 5 summarises the distribution of gastroenterology or hepatology topics in relation to the four categories. The majority of top-cited articles were research papers (n=38, 76%). The remaining were reviews (n=8, 16%) and articles (n=3, 6). Only one article (2%) was an educational guide. The topics can be summarised as follows: colorectal cancer (n=12, 24%), chronic hepatitis and viral hepatitis (n=9, 18%), hepatocellular carcinoma (n=7, 14%), inflammatory bowel disease (n=6, 12%), gastritis, gastric ulcer and H. pylori (n=4, 8%), and Escherichia coli and diarrhoeal diseases (n=3, 6%). The distribution of the remaining topics is shown in table 5.

Table 4.

Top-cited articles by searching keywords for all journals listed in the Science Citation Index Expanded database (list B): by article type and year of publication*

Article type Year of publication: number of articles (references)
1945–1975 1976–1981 1982–1987 1988–1993 1994–1999 2000–2005 2006–2011 Total (%)
Article 293 27 128 3 (6)
Review 431 85 101 102 3103 110 113 132 8 (16)
Practical Guidelines 125 1 (2)
Research 181 326 29 119 2108 112 780 90 92 105 106 109 116 933 88 89 94 97 98–100 111 1530 79 82,83 86 87,91 95 96 104 107 114 115 117 118 184 38 (76)
Total (%) 1 (2) 3 (6) 2 (4) 7 (14) 15 (30) 20 (40) 2 (4) 50 (100)

*The search was conducted on 27 May 2015. Articles with reference numbers25–33 appeared in lists A and B but with different rankings.

Table 5.

Top-cited articles by searching keywords for all journals listed in the Science Citation Index Expanded database (list B): by article topic and category*

Topic† Category: number of articles (references)
Article Review Practical guidelines Research Total (%)
Gastritis, gastric ulcer, Helicobacter pylori 193 388 92 118 4 (8)
Escherichia coli and diarrhoeal disease 1101 286 96 3 (6)
Chemotherapy and gastrointestinal toxicity 1107 1 (2)
Stromal tumours 1104 1 (1.9)
Pancreatic cancer 194 1 (1.9)
Inflammatory bowel disease 1113 529 87 91 99 111 6 (12)
Colorectal cancer 285 102 1033 79 95 100 105 106 109 114 116 117 12 (24)
Chronic hepatitis and viral hepatitis 127 131 726 80 82 83 90 98 115 9 (18)
Fatty liver disease 1110 130 2 (4)
Oesophageal varices 181 1 (2)
Bilirubin and hepatic transporters 2108 112 2 (4)
Haemochromatosis 197 1 (2)
Hepatocellular carcinoma 128 232 103 125 384 89 119 7 (14)
Total (%) 3 (6) 8 (16) 1 (0) 38 (76) 50 (100)

*The search was conducted on 27 May 2015. Articles with reference numbers25–33 appeared in lists A and B, but with different rankings.

†Some studies covered more than one topic and were classified depending on the aim of the study and the main outcomes.

The top-cited articles were published in 17 journals. Of these, three were specialised in the field (n=number of articles, %): Hepatology (n=4, 8%), Gastroenterology (n=3, 6%) and Journal of Hepatology (n=2, 4%). The majority were published in journals not dedicated to the specialty (n=number of articles, %): New England Journal of Medicine (n=16, 32%), Science (n=5, 10%), Nature (n=5, 10%), Lancet (n=3, 6%), Cell (n=2, 4%), Journal of Clinical Oncology (n=2, 4%), Nature Genetics (n=1, 2%), British Journal of Surgery (n=1, 2%), DNA Research (n=1, 2%), Clinical Microbiology Reviews (n=1, 2%), Cancer Research (n=1, 2%), Annals of Internal Medicine (n=1, 2%), American Journal of Surgical Pathology (n=1, 2%) and Proceedings of the National Academy of Sciences of the USA (n=1, 2%) (see online supplementary appendix 2).

The most frequently cited article was ‘Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer’, by Hurwitz et al,79 published in New England Journal of Medicine and cited 5500 times over 11 years. The article ranked 50 was ‘Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas’, by Eberhart et al,33 published in Gastroenterology and cited 1929 times over 21 years. There was no correlation between the number of citations of these papers and the number of years since publication (R2=0.00202, p=0.757) (figure 1G). Most articles were from universities in the USA (n=32, 64%), Spain (n=4, 8%), the UK (n=3, 6), France (n=2, 4%), Japan (n=2, 4%), Germany, Italy, Finland, Greece, Canada, Belgium and Taiwan (n=1, 2%) for each country.

Some authors contributed to more than one article in list B. In addition to the five articles published by Bruix and included in list A,25 28 39 52 63 were two articles in list B.84 103 These articles were on hepatocellular carcinoma. Interestingly, 24 authors had authored or co-authored more than one article in list A and 29 authors had more than one article in list B. Those who contributed to both lists were: Bond JH, Bruix J, Llovet JM, Mann SM, JP, Miller LL, Rosen L and Winawer SJ (table 6).

Table 6.

Authors and co-authors of two or more articles of top-cited articles in gastroenterology and hepatology identified by searching gastroenterology and hepatology journals (list A) or by searching keywords for all journals listed in the Web of Science (list B)*

List A
List B
Author's name† Number references
Author's name Number references
First author Co-author First author Co-author
Bedossa P 236 78 Albrecht JK 282 98
Bond JH‡ 247 50 Blanke CD 2104 117
Bruix J‡ 325 28 39 252 63 Bond JH 1105 116
Desmet V 131 127 Bruix J 284 103
Fletcher R 247 50 Choo QL 180 190
Ishak K 127 126 Diago M 283 115
Lok AS 244 66 158 Fehrenbach L 279 117
Llovet JM‡ 252 63 128 Goodman ZD 282 98
Lynch HT 249 55 Gordon SC 282 98
Manns M‡ 131 Hamilton SR 22 10 106
McCullough JA 230 42 Hüssinger D 283 84
McMahon BJ 244 66 Kinzler KW 185 1100
Mecklin JP‡ 149 55 Kuo G 190 180
Miller LL‡ 147 Lin A 283 115
Rosen L‡ 147 Ling M 282 98
Sherman M 325 28 39 Llovet JM 284 103
Strader DB 159 141 Manns M 182
Talley NJ 156 57 Mazzaferro V 189 184
Thomas DL 241 59 McHutchison JG 198 182
Thompson WG 140 56 Mecklin JP 1106
Vakil N 169 170 Miller LL 186 117
Vasen HF 249 55 Moore MJ 294 117
Winawer SJ‡ 247 50 Rosen L 1117
Woolf S 247 50 Rustgi VK 282 98
Santoro A 284 95
Shiffman M 382 83 98
Williams R 271 81
Winawer SJ 1105
Zeuzem S 284 115

*The table is limited to authors and co-authors of two or more articles in lists A and/or B regardless to the category of the article.

†Author's name, family name of first author, abbreviations of first or first and second names.

‡The authors have contributed to articles in lists A and B.

Based on the number of citations attracted by top-cited articles in list B, we looked at the ranking of these articles in the journals they were published in (the 14 journals that were not specialised in gastroenterology and hepatology). It was interesting to note that five of the top-cited articles were ranked number 1 in their respective journals (ranked number 1 means an article receiving the highest number of citations compared to all articles published in the journal). These articles were published in the following five journals—Journal Impact Factor (JIF)reference British Journal of Surgery 5.542,81 American Journal of Surgical Pathology 5.145,93 Journal of Clinical Oncology 18.428,94 DNA Research 5.47796 and Clinical Microbiology Reviews 17.406.101

Eleven top-cited articles were ranked between 2 and 50 in the journals they were published in. The articles were published in the following eight journals—JIFreference: Journal of Clinical Oncology 18.428,94 114 Annals of Internal Medicine 17.810,115 Lancet 45.217,82 103 Nature Genetics 29.352,97 New England Journal of Medicine 55.873,79 83 84 Cancer Research 9.329,102 Cell 32.24285 and Science 33.611.80

Comparing lists A and B

The total number of citations for all the 54 articles included in list A was 81324.0 and 138012.0 for the 50 articles in list B. The median number (IQR) of citations for top-cited articles in list A was 1340.0 (IQR=529.5) and 2585.5 (IQR=739.2) for list B.

Several universities or research centres contributed to more than one article. For example, Mayo Clinic and Mayo Foundation, Rochester, Minnesota;34 57 67 110 and the University of Michigan Medical Center, Michigan,44 58 66 91 each contributed four articles. Other research centres contributed two articles each. These were: The National Center Institute, Bethesda, Maryland;30 108 University Hospital of Cleveland, Cleveland;42 46 The Upjohn Company, Kalamazoo, Michigan;37 74 Duke University Center, Durham, North Carolina;43 79 Johns Hopkins Oncology Center, Baltimore, Maryland;85 100 and University of Wisconsin, Madison, Wisconsin.69 86 In Spain, the top-cited articles originated from the University of Barcelona25 39 52 and Barcelona-Clinic Liver Cancer Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Liver Unit, Hospital Clínic, Barcelona, Catalonia.28 52 63

Figure 2 shows the citations (mean±SD) attracted by top-cited articles in lists A and B for each type of paper (Practical Guide, Research, Article and Review). Further analysis showed no significant differences between the number of citations attracted by each type in the two lists (p=0.803).

Figure 2.

Figure 2

Citations (mean±SD) attracted by top-cited papers in lists A and B for each paper type.

Table 7 summarises the type of research in both lists. In list B, randomised controlled trials (n=15, 30%) and cohort studies (n=8, 16%) were dominant, while in list A, cross-sectional studies (n=3, 5.9%), a case–control study (n=1, 2%), experimental studies (n=9, 17.6%) and causal-comparative studies (n=5, 9.8%) were observed. Four research studies were identified in both lists.26 29 30 33 The inter-rater agreement between evaluators had a Cohen κ coefficient of 0.76–0.84.

Table 7.

Top-cited research articles in gastroenterology and hepatology identified by searching gastroenterology and hepatology journals (list A) or by searching keywords for all journals listed in the Web of Science (list B): by article topic and research type*

Topic Research type: number of articles (references)
Cross-sectional study Case–control study Cohort study Randomised controlled trial Experimental study Causal-comparative study
Gastro-oesophageal reflux disease 157
Gastritis, gastric ulcer, Helicobacter pylori 292 118 245 88
Prostaglandins and gastric protection 137
Functional gastrointestinal disorders 156
Escherichia coli and diarrhoeal disease 286 96
Chemotherapy and gastrointestinal toxicity 1107
Pancreatic cancer 194
Intestinal ischaemia 165
Inflammatory bowel disease 1111 660 68 87 91 99 113 229 61
Colorectal cancer 133 2105 106 679 95 104 114 116 117 351 100 109
Stromal tumours
Chronic hepatitis and viral hepatitis 458 73 78 90 482 83 98 115 326 36 80
Fatty liver disease 248 62 142 130
Oesophageal varices 181
Bilirubin and hepatic transporters 1108
Haemochromatosis 197
End-stage liver disease and liver failure 134 171
Hepatocellular carcinoma 289 119 272 84 154
Total 4 1 12 15 21 5

*The research papers26 29 30 33 were identified in lists A and B and each was recorded once only in this table.

Discussion

The aim of this study was to identify the 50 top-cited articles in gastroenterology and hepatology, and to gain insight into the characteristics of the top-cited articles in the field. Citation analysis may offer the opportunity to gain insight into peer recognition of articles that added to the discipline. To ensure that our search had included articles published in journals other than those dedicated to the discipline, a second search was conducted using keywords (list B). The latter search covered all journals listed in the SCI-Expanded regardless of specialty. The number of citations attracted by articles included in list B was significantly higher than those in list A. This may be proportional to the JIF of the journals in which the articles were published. Interestingly, the articles in list A were published in 10 journals with the highest JIF in the category ‘Gastroenterology and Hepatology’ listed in the 2014 JCR. The finding that the majority of articles in list B were from journals not in the field, reflects the integrative nature of the specialty with the role of basic sciences and clinical studies in the development of Gastroenterology and Hepatology. It also shows the interest of editors and readers in journals such as New England Journal of Medicine, Annals of Internal Medicine and Lancet in gastroenterology and hepatology topics.

The study provided an insight into the trends in publications over the past 60–70 years. Top-cited articles from the 1950s to the late 1970s dealt primarily with animal models for the study of gastric ulcerations,45 cytoprotection of gastric mucosa by prostaglandins,37 74 animal models for intestinal ischaemia,65 the development of a numerical scoring system for assessing histological activity in patients with chronic active hepatitis26 and the development of Crohn's disease activity index.29 During the 1980s to early 1990s, the articles focused on animal models of inflammation and ulcerations in the colon,60 61 68 localisation of the multidrug-resistant gene product, p-glycoprotein,108 and the biology of bilirubin,112 non-A and non-B viral hepatitis,80 90 and colorectal cancer.49 51 105 106 109 116

From 1994 to 2005, top-cited articles focused on three hepatology topics: (1) steatohepatitis and fatty liver,30 35 38 42 48 62 110 (2) hepatocellular carcinoma,25 28 52 63 72 76 89 103 and (3) viral hepatitis C diagnosis and treatment,36 58 59 73 78 82 83 98 115 as well as three gastroenterology topics: (1) colorectal cancer,47 50 75 79 85 95 102 104 114 117 (2) inflammatory bowel disease and colitis,46 67 87 99 113 and E. coli and diarrhoeal diseases.86 96 101 The studies after 2006 continued to explore new aspects related to hepatocellular cancer,32 39 54 hepatitis B44 66 and hepatitis C.41

With regard to clinical relevance, the articles reflect the hidden burden of chronic hepatitis B and C infections, which the former US Assistant Secretary for Health, Dr Howard Koh, described as the ‘Silent Epidemic’,120 and highlight the need for strategies to prevent and manage liver cancer121 and colorectal cancer. In USA, over 1.3 million people suffer from inflammatory bowel disease and, despite extensive research in this area, we are still unable to identify the exact cause of the disease or to have clear preventive strategies or an effective cure.122 In the USA, colorectal cancer is the second leading cause of cancer-related deaths in males and in females. It is the third most common cancer in men and in women.123 Therefore, the scientific and research relevance of the top-cited articles identified in the two lists reflects the emerging needs of these areas and the new developments in our understanding of these disorders.

Although it may take 15 years or more for articles to reach a peak in the overall citation number,124 it was noted that a number of top-cited articles in both lists were only 8 or less years old.32 39 41 44 54 66 70 77 84 Only four articles were published after 2007. However, the article by Shay et al,45 on animal model for the study of gastric ulcers, was 70 years old (published in 1945). Careful scrutiny showed that the article is still attractive to researchers and was cited 10 times in 2015, 23 times in 2014 and 25 times in 2013. Top-cited articles are frequently cited but this tendency does not necessarily indicate that these papers are great. For example, the most cited work in history is the paper by Lowry et al, a 1951 paper describing an assay to determine the amount of protein in a solution. It has gathered, at the time of submitting this manuscript, 311 819 citations, although several new techniques for measuring protein in a solution and several modified techniques to this method have been developed and described in the literature over the past 65 years.125 However, such papers are exceptions and do not represent a general trend.

As shown from this study, there was no correlation between the number of citations and the number of years since the paper was published. This was demonstrated for articles included in both lists. The finding may be related to the tendency of researchers to cite particular papers. This may become standard practice to make clearer to other scientists the type of methods these individuals followed in their research.18 It has been shown from this study that the mean numbers of citations of articles published after the year 2000 are higher than those published before 2000, not necessarily because of their quality but due to the tendency of researchers to preferentially cite the most recent studies.

This study also showed no correlation between number of authors or number of grants received and number of citations, but demonstrated strong correlations between the number of institutes involved or number of countries and the number of citations. Females were under-represented in authorship (45 vs 254, p=0.004). In neither list were significant differences found between the number of citations attracted by each type of paper—Practical Guide, Research, Article and Review—which may highlight the equal significance and usefulness of each type to researchers and clinicians.

These findings are consistent with those of Danthi et al,126 who, in a large cohort of the National Heart, Lung, and Blood Institute (NHLBI) grant-funded research, reported that they were unable to find a monotonic association between better percentile ranking and higher scientific impact as assessed by citation metrics.126 Again, Fortin and Currie,127 in a study evaluating how scientific impact scales with funding, concluded that their findings are inconsistent with the hypothesis that larger grants lead to larger discoveries. The issue of female authorship in major academic gastroenterology journals has been recently studied. The authors found that the percentage of US female physician authors of original research in major gastroenterology journals is lower than expected, although it has increased over time.128

While writing this study, we came across a recently published article by Tang et al,129 who used three key search words to identify top-cited article on the digestive system. The method used was briefly described and there was no list of top-cited articles to compare with our list. However, it was noticed that, out of a list of 100 articles, Tang et al identified only eight articles from Gastroenterology, while this study identified 26 articles among top-cited articles in list A. They identified five institutions with two or more articles, while in this study, more than 10 centres were identified. They reported only two top-cited articles each from Mayo Clinic and Mayo Foundation, Rochester, Minnesota, and from the University of Michigan Medical Center, Michigan, while this study identified four articles from each of these institutions. Several centres that contributed to more than one article were not mentioned in Tang's study. Also, they only identified six authors who had authored or co-authored two or more top-cited articles, while, as per the results from this study, 24 authors in list A and 29 authors in list B had authored or co-authored more than one top-cited article (table 6). These differences may be related to differences in the methodology used and possibly the depth in analysing data collected.

However, this study is not without limitations. First, the search used was based on journals with high impact factor. This may have contributed to the increased number of articles from Western countries, especially the USA, the UK and Canada. Therefore, articles in languages other than English, which may have impact in the field, were not included. However, our findings show that Spain was the second country that contributed to most-cited articles in lists A and B. Recently, Iñigo and García-Samaniego, in an elegant article, conducted a bibliometric analysis of publications in gastroenterology and hepatology in Spain, from 2000 to 2009. The paper was written in the Spanish language.20 Second, authors’ self-citations were not excluded from the total number of citations, and absolute number of citations was used. Third, the search was conducted using the Science Citation Index Expanded database, and there is the possibility that the database filter is not sensitive enough to the search words. However, in this study, 69 journals specialised in the field were searched and more than 40 keywords were used in the search with the aim to maximise the yield. Fourth, the 50 top-cited articles in the two lists represent an arbitrary number and the findings represent the outcomes at the time of conducting the search. One of the strengths of this study is the search for the top 50 frequently cited papers, using two search methods.

Conclusions

The citation analysis in this study compiled two lists of the top 50 highly cited articles in gastroenterology and hepatology. The first list (list A) was constructed by searching 69 journals in the field. List B was constructed by searching the Science Citation Index Expanded database, using keywords. The citations varied from 1049 and 2959 in list A and from 1929 to 5500 in list B. The articles were published between 1945 and 2011, with the number of articles increasing progressively from 1988 to 2011. In both lists, research papers dominated top-cited articles. Randomised controlled trials and cohort studies dominated research in list B, while in lit A, cross-sectional studies, a case–control study and experimental studies were observed. The number of authors or co-authors with more than one article was 24 in list A and 29 in list B. Articles in list B were mainly published in New England Journal of Medicine, Science and Nature. The articles came from over 12 different countries, with the USA most frequently represented followed by Spain. While no correlations were found between the number of authors or the number of grants received, and the number of citations, strong correlations were found between the number of institutes or the number of countries involved, and the number of citations. In neither list was there significant correlation between the number of citations and the number of years since publishing. However, the mean number of citations tended to be higher in papers published after the year 2000, possibly indicating the significance of scientific content and the tendency of researchers to cite recently published work.

Acknowledgments

The authors would like to thank Diana Azer for her assistance and review of the manuscript. They also thank Dr Lily Scott for her assistance in this work and Ms Mae Eustaquio for secreterial assistance.

Appendix 1

Top-Cited Gastroenterology and Hepatology Articles Published in Gastroenterology and Hepatology Journals, identified by Category Search in the Web of Science™, Ranked from 1 to 50 (List A).

Rankc Author, Year [Reference] Title (Journal) Category Number of citations Origin: First author's organisation, location (country)
1 Bruix and Sherman, 200525 Management of hepatocellular carcinoma (Hepatology) Practice guideline 2,959 University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, (Spain).
2 Knodell et al, 198126 Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. (Hepatology). Research 2,890 Gastroenterology Section, Veterans Administration Medical Center, Minneapolis, Minnesota, (United States).
3 Ishak et al, 199527 Histological grading and staging of chronic hepatitis. (Journal of Hepatology). Article 2,603 Armed Forces Institute of Pathology, Washington, (United States).
4 Bruix et al, 200128 Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver ( Journal of Hepatology) . Article 2,467 Liver Unit, Digestive Disease Institute, Hospital Clinic, IDIBAPS, Barcelona, Catalonia, (Spain).
5 Best et al, 197629 Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study (Gastroenterology) Research 2,263 University of Colorado Medical Center, Denver, Colorado, (United States)
6 Kleiner et al, 200530 Design and validation of a histological scoring system for nonalcoholic fatty liver disease. (Hepatology) Research 2,222 Laboratory of Pathology, National Cancer Institute, Bethesda, MD, (United States)
7 Desmet et al, 199431 Classification of chronic hepatitis: diagnosis, grading and staging. (Hepatology). Review 2038 Department of Pathology, Catholic University of Leuven, (Belgium).
8 El-Serag and Rudolph, 200732 Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (Gastroenterology). Review 2,028 Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine, Houston, Texas, (United States)
9 Eberhart et al, 199433 Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. (Gastroenterology) Research 1,929 Vanderbilt University Medical Center, Nashville, Tennessee (United States).
10 Kamath et al, 200134 A model to predict survival in patients with end-stage liver disease (Hepatology). Research 1,916 Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, (United States).
11 Day and James, 199835 Steatohepatitis: a tale of two "hits"? (Gastroenterology) Article 1,808 Centre for Liver Research Newcastle Upon Tyne, (United Kingdom)
12 Bedossa and Poynard, 199636 An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. (Hepatology). Research 1,783 Service d'Anatomie Pathologique, Hôpital de Bicêtre, Le Kremlin- Bicêtre, (France).
13 Robert et al, 197937 Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. (Gastroenterology). Research 1,722 The Upjohn Company, Kalamazoo, Michigan (United States).
14 Brunt et al, 199938 Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions (American Journal of Gastroenterology). Review 1,681 Department of Pathology, Saint Louis University School of Medicine, Missouri, (United States).
15 Bruix et al, 201139 Management of hepatocellular carcinoma: an update. (Hepatology). Practice guideline 1,642 Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, (Spain).
16 Longstreth et al, 200640 Functional bowel disorders (Gastroenterology). Practice guidelines 1,616 Kaiser Permanente Medical Care Program, San Diego, California, (United States).
17 Ghany et al, 200941 Diagnosis, management, and treatment of hepatitis C: an update. (Hepatology). Practical guideline 1,603 National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (United States).
18 Matteoni et al, 199842 Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. (Gastroenterology). Research 1,565 University Hospitals of Cleveland, Department of Medicine, Cleveland, Ohio, USA. (United States)
19 Cotton et al, 199143 Endoscopic sphincterotomy complications and their management: an attempt at consensus. (Gastrointestinal Endoscopy). Review 1,515 Department of Medicine, Duke University Medical Center, Durham, North Carolina (United States).
20 Lok and McMahon, 200744 Chronic hepatitis B (Hepatology). Practical guideline 1,511 University of Michigan Medical Center, Ann Arbor, MI (United States).
21 Shay et al, 194545 A simple method for the uniform production of gastric ulceration in the rat (Gastroenterology). Research 1,455 Research Institute Temple University, School of Medicine, Philadelphia (United States).
22 Fiocchi, 199846 Inflammatory bowel disease: etiology and pathogenesis. (Gastroenterology). Review 1,443 University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Ohio, (United States).
23 Winawer et al, 199747 Colorectal cancer screening: clinical guidelines and rationale (Gastroenterology). Practice guideline 1,388 Gastroenterology and Nutrition Service Memorial Sloan-Kettering Cancer Center, New York, (United States).
24 Browning et al, 200448 Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity (Hepatology). Research 1,373 Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (United States).
Vasen et al, 199149 The International Collaborative Group on Hereditary Non- Polyposis Colorectal Cancer (ICG-HNPCC). (Diseases of the Colon & Rectum) Article 1,373 The Netherlands Foundation for the Detection of Hereditary Tumours, Utrecht/Leiden Centraal, The Netherlands.
25 Winawer et al, 200350 Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence (Gastroenterology). Practice guidelines 1,348 Memorial Sloan-Kettering Cancer Center, and Weill Medical College of Cornell University, New York, (United States).
26 Hidalgo et al, 198951 Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. (Gastroenterology) Research 1,345 Department of Pharmaceutical Chemistry, University of Kansas, (United States)
27 Llovet and Bruix, 200352 Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. (Hepatology). Review 1,335 Barcelona-Clínic Liver Cancer Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Catalonia, (Spain).
28 Marsh, 199253 Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue') (Gastroenterology). Article 1,323 University Department of Medicine, Manchester University School of Medicine, (United Kingdom)
29 Meng et al, 200754 MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. (Gastroenterology). Research 1,307 Scott and White Clinic, Texas A&M University System Health Science Center College of Medicine, Temple, Texas (United States).
30 Vasen et al, 199955 New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. (Gastroenterology). Practical guidelines 1,280 The Netherlands Foundation for the Detection of Hereditary Tumours, Leiden, (The Netherlands).
Drossman et al, 199356 U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. (Digestive Diseases and Sciences) Research 1,280 University of North Carolina, Division of Digestive Diseases, Chapel Hill (United States)
31 Locke et al, 199757 Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. (Gastroenterology). Research 1,278 Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, (United States).
32 Wai et al, 200358 A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. (Hepatology). Research 1,232 Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI (United States).
33 Strader et al, 200459 Diagnosis, management, and treatment of hepatitis C. (Hepatology).. Practical guideline 1,212 Fletcher Allen Health Care University of Vermont College of Medicine, Burlington, VA, (United States).
34 Morris et al, 198960 Hapten-induced model of chronic inflammation and ulceration in the rat colon. (Gastroenterology). Research 1,197 Queen's University, Kingston, Ontario, (Canada).
35 Krawisz et al, 198461 Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. (Gastroenterology). Research 1,195 The Jewish Hospital of St. Louis at Washington University School of Medicine, St. Louis, Missouri (United States).
36 Marchesini et al, 200362 Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. (Hepatology). Research 1,193 Unit of Metabolic Diseases and Department of Internal Medicine, Alma Mater Studiorum University of Bologna, Bologna, (Italy).
37 Llovet et al, 199963 Prognosis of hepatocellular carcinoma: the BCLC staging classification. (Seminars in Liver Disease). Review 1,177 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Catalonia, (Spain).
Lavanchy, 200464 Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. (Journal of Viral Hepatitis) Review 1,177 World Health Organization, Communicable Disease Surveillance and Response, Geneva, (Switzerland).
38 Granger et al, 198165 Superoxide radicals in feline intestinal ischemia. (Gastroenterology). Research 1,176 University of South Alabama, Mobile, Alabama (United States).
39 Lok and McMahon, 200966 Chronic hepatitis B: update 2009. (Hepatology). Practical guideline 1,168 University of Michigan Medical Center, Ann Arbor, MI (United States).
40 Loftus, 200467 Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. (Gastroenterology). Review 1,161 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota (United States).
41 Okayasu et al, 199068 A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. (Gastroenterology). Research 1,158 Department of Pathology, School of Medicine, Tokyo Medical and Dental University, (Japan.)
42 Vakil et al, 200669 The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus (American Journal of Gastroenterology). Practical guideline 1,145 University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, (United States).
43 Malfertheiner et al, 200770 Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. (Gut) Practical guideline 1,143 Universitat Magdeburg, Medizinische Fakultat, Zentrum fu?r Innere Medizin, Klinik fu?r Gastroenterologie, Hepatologie und Infektiologie, Leipziger Magdeburg, (Germany)
44 O'Grady et al,198971 Early indicators of prognosis in fulminant hepatic failure. (Gastroenterology). Research 1,132 Liver Unit, King's College School of Medicine, London, (United Kingdom).
45 Lo et al, 200272 Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. (Hepatology). Research 1,122 Center for the Study of Liver Disease, University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, (China).
46 Castéra et al, 200573 Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. (Gastroenterology). Research 1,101 Service d'Hépato-gastroentérologie, Hôpital Haut Lévêque, C. H. U. Bordeaux, Pessac, (France).
47 Robert, 197974 Cytoprotection by prostaglandins. (Gastroenterology). Article 1,096 Department of Experimental Biology, The Upjohn Company, Kalamazoo, Michigan, (United States).
48 Eaden et al, 200175 The risk of colorectal cancer in ulcerative colitis: a meta-analysis (Gut). Review 1,081 Gastrointestinal Research Unit, Leicester General Hospital, Leicester (United Kingdom).
49 Bosch et al, 200476 Primary liver cancer: worldwide incidence and trends (Gastroenterology). Review 1,071 IDIBELL Institut Català d'Oncologia, Avda. Barcelona, (Spain).
50 Baggio and Drucker, 200777 Biology of incretins: GLP-1 and GIP (Gastroenterology). Review 1,049 Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada.
Bedossa et al, 200378 Sampling variability of liver fibrosis in chronic hepatitis C. (Hepatology). Research 1,049 Service d'Anatomie Pathologique, Hôpital Bicêtre, Le Kremlin- Bicêtre, (France).

Appendix 2

Top-Cited Gastroenterology and Hepatology Articles Published Across All Journals Listed in the Web of Science™, Identified by Keyword Search, Ranked From 1 to 50 (List B).

Rankc Author, Year [Reference] Title (Journal) Category Number of citations Origin: First author's organisation, location (country)
1 Hurwitz et al, 200479 Bevacizumab plus irinotecan, fluorouracil, and leucovorin formetastatic colorectal cancer (New England Journal of Medicine). Research 5,500 Duke University Medical Center, Durham, North Carolina, (United States).
2 Choo et al, 198980 Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome (Science). Research 5,227 Chiron Corporation, Emeryville, California, (United States)
3 Pugh et al, 197381 Transection of the oesophagus for bleeding oesophageal varices. (British Journal of Surgery) Research 4,630 King's College Hospital and Medical School, London, (United Kingdom).
4 Manns et al, 200182 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial (Lancet). Research 4,438 Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, (Germany).
5 Fried et al, 200283 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. (New England Journal of Medicine). Research 4,363 University of North Carolina, Chapel Hill (United States).
6 Llovet et al, 200884 Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine). Research 3,355 Barcelona Clínic Liver Cancer Group, Liver Unit, Barcelona, (Spain).
7 Kinzler and Vogelstein, 199685 Lessons from hereditary colorectal cancer (Cell). Review 3,325 The Johns Hopkins Oncology Center, Baltimore, Maryland (United States).
8 Perna et al, 200186 Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. (Nature). Research 3,306 Genome Center of Wisconsin, University of Wisconsin, Madison, (United States)
9 Hugot et al, 200187 Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. (Nature). Research 3,185 Fondation Jean Dausset CEPH, Paris, (France).
10 Tomb et al, 199788 The complete genome sequence of the gastric pathogen Helicobacter pylori. (Nature). Research 3,173 Institute for Genomic Research, Rockville, Maryland 20850, (United Stats).
11 Mazzaferro et al, 199689 Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. (New England Journal of Medicine). Research 3,154 Department of Surgery, National Cancer Institute, Milan, (Italy).
12 Bruix and Sherman, 200525 Management of hepatocellular carcinoma (Hepatology) Practice guideline 2,959 University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, (Spain).
13 Kuo et al, 198990 An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. (Science). Research 2,951 Chiron Corporation, Emeryville, California, (United States).
14 Ogura et al, 200191 A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. (Nature). Research 2,917 The University of Michigan Medical School, Ann Arbor, Michigan, (United States).
15 Parsonnet et al, 199192 Helicobacter pylori infection and the risk of gastric carcinoma. (New England Journal of Medicine). Research 2,913 Department of Medicine, Stanford University School of Medicine, California, (United States).
16 Knodell et al, 198126 Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. (Hepatology). Research 2,890 Gastroenterology Section, Veterans Administration Medical Center, Minneapolis, Minnesota, (United States).
17 Dixon et al, 199693 Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. (The American Journal of Surgical Pathology). Article 2,874 University of Leeds, (United Kingdom).
18 Burris et al, 199794 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. (Journal of Clinical Oncology). Research 2,830 Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, (United States).
19 Cunningham et al, 200495 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (New England Journal of Medicine). Research 2,772 Royal Marsden Hospital, London, (United Kingdom).
20 Hayashi et al, 200196 Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. (DNA Research). Research 2,755 Department of Microbiology, Miyazaki Medical College, Kiyotake, (Japan).
21 Feder et al, 199697 A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. (Nature Genetics). Research 2,744 Mercator Genetics, Inc., Menlo Park, California, (United States)
22 McHutchison et at, 199898 Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. (New England Journal of Medicine). Research 2,639 Division of Gastroenterology- Hepatology, Scripps Clinic and Research Foundation, La Jolla, California, (United States).
23 Groux et al, 199799 A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. (Nature) Research 2,627 DNAX Research Institute of Molecular and Cellular Biology, Inc., Human Immunology Department, Palo Alto, California, (United States).
24 Morin et al, 1997100 Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. (Science) Research 2,613 Howard Hughes Medical Institute and Johns Hopkins Oncology Center, Baltimore, Maryland, (United States).
25 Ishak et al, 199527 Histological grading and staging of chronic hepatitis. (Journal of Hepatology). Article 2,603 Armed Forces Institute of Pathology, Washington, (United States).
26 Nataro and Kaper, 1998101 Diarrheagenic Escherichia coli. (Clinical Microbiology Reviews). Review 2,568 Department of Medicine, University of Maryland School of Medicine, Baltimore, (United States).
27 Boland et al, 1998102 A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. (Cancer Research) Review 2,559 University of California, San Diego, (United States).
28 Bruix et al, 200128 Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver ( Journal of Hepatology). Article 2,467 Liver Unit, Digestive Disease Institute, Hospital Clinic, IDIBAPS, Barcelona, Catalonia, (Spain).
29 Llovet et al, 2003103 Hepatocellular carcinoma. (Lancet). Review 2,401 Barcelona-Clínic Liver Cancer Group, Liver Unit, Digestive Disease Institute, IDIBAPS, University of Barcelona, Barcelona, (Spain).
30 Demetri et al, 2002104 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (New England Journal of Medicine). Research 2,383 Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA, (United States).
31 Winawer et al, 1993105 Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. (New England Journal of Medicine). Research 2,355 Gastroenterology and Nutrition Service, Memorial Sloan-Kettering Cancer Center, New York, (United States).
32 Aaltonen et al, 1993.106 Clues to the pathogenesis of familial colorectal cancer. (Science). Research 2,337 Department of Medical Genetics, University of Helsinki, (Finland).
33 Bombardier et al, 2000107 Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. (New England Journal of Medicine). Research 2,315 Institute for Work and Health, Mount Sinai Hospital, and the University Health Network, Toronto, ON, (Canada).
34 Best et al, 197629 Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study (Gastroenterology) Research 2,263 University of Colorado Medical Center, Denver, Colorado, (United States)
35 Thiebaut et al, 1987108 Cellular localization of the multidrug-resistance gene product P- glycoprotein in normal human tissues (Proceedings of the National Academy of Sciences of the United States of America). Research 2,245 Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD, (United States).
36 Kleiner et al, 200530 Design and validation of a histological scoring system for nonalcoholic fatty liver disease. (Hepatology) Research 2,222 Laboratory of Pathology, National Cancer Institute, Bethesda, MD, (United States)
37 Fishel et al, 1993109 The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. (Cell). Research 2,207 Department of Microbiology and Molecular Genetics Markey Center for Molecular Genetics University of Vermont Medical School Burlington, (United States)
38 Angulo, 2002110 Nonalcoholic fatty liver disease. (New England Journal of Medicine). Review 2,202 Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota, (United States).
39 Targan et al, 1997111 A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. (New England Journal of Medicine). Research 2,173 Cedars-Sinai Medical Center, Los Angeles, California (United States).
40 Stocker et al, 1987112 Bilirubin is an antioxidant of possible physiological importance (Science). Research 2147 University of California, Berkeley, Department of Biochemistry, Berkeley, California (United States).
41 Podolsky, 2002113 Inflammatory bowel disease. (New England Journal of Medicine). Review 2,118 Gastrointestinal unit and the Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, (United States).
42 de Gramont et al, 2000114 Leucovorin and fluorouracil with or without oxaliplatin as first- line treatment in advanced colorectal cancer. (Journal of Clinical Oncology). Research 2,094 Service de Médecine Interne-Oncologie, Hôpital Saint-Antoine, Paris, (France).
43 Hadziyannis et al, 2004115 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. (Annals of Internal Medicine) Research 2,063 Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, (Greece).
44 Mandel et al, 1993116 Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. (New England Journal of Medicine). Research 2,047 Division of Environmental and Occupational Health, University of Minnesota, Minneapolis, (United States).
45 Saltz et al, 2000117 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. (New England Journal of Medicine). Research 2,040 Memorial Sloan-Kettering Cancer Center, New York, (united States).
46 Uemura et al, 2001118 Helicobacter pylori infection and the development of gastric cancer. (New England Journal of Medicine). Research 2,039 Department of Gastroenterology, Kure Kyosai Hospital, Kure City, (Japan)
47 Desmet et al, 199431 Classification of chronic hepatitis: diagnosis, grading and staging. (Hepatology). Review 2038 Department of Pathology, Catholic University of Leuven, (Belgium).
48 Beasley et al, 1981119 Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. (Lancet). Research 2,029 University Washington Medical Research Unit, Taipei, Taiwan.
49 El-Serag and Rudolph, 200732 Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (Gastroenterology). Review 2,028 Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine, Houston, Texas, (United States)
50 Eberhart et al, 199433 Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. (Gastroenterology) Research 1,929 Vanderbilt University Medical Center, Nashville, Tennessee (United States).

Footnotes

Contributors: SAA started the design of the study and contributed to its methodology. SAA and SA searched the databases, collected the data, analysed the findings and created the two lists. SAA and SA also interpreted the findings, ranked the articles, created the tables and figures and drafted the manuscript, as well as contributed to the revision of the manuscript and approved the final manuscript for submission.

Funding: This work was supported by the College of Medicine Research Center, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia.

Competing interests: None declared.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: No additional data are available.

References

  • 1.Ioannidis JP, Boyack KW, Small H et al. . Bibliometrics: is your most cited work your best? Nature 2014;514:561–2. 10.1038/514561a [DOI] [PubMed] [Google Scholar]
  • 2.Patsopoulos NA, Ioannidis JP, Analatos AA. Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ 2006;332:1061–4. 10.1136/bmj.38768.420139.80 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Garfield E. Fortnightly review: how can impact factors be improved? BMJ 1996;313:411–13. 10.1136/bmj.313.7054.411 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Garfield E. Is citation analysis a legitimate evaluation tool? Scientometrics 1979;1:359–75. 10.1007/BF02019306 [DOI] [Google Scholar]
  • 5.Nicholson JM, Ioannidis JP. Research grants: conform and be funded. Nature 2012;492:34–6. 10.1038/492034a [DOI] [PubMed] [Google Scholar]
  • 6.McVeigh ME, Mann SJ. The journal impact factor denominator: defining citable (counted) items. JAMA 2009;302:1107–9. 10.1001/jama.2009.1301 [DOI] [PubMed] [Google Scholar]
  • 7.van Leeuwen T. Discussing some basic critique on Journal Impact Factors: revision of earlier comments. Scientometrics 2012;92:443–55. 10.1007/s11192-012-0677-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.King DA. The scientific impact of nations. Nature 2004;430:311–16. 10.1038/430311a [DOI] [PubMed] [Google Scholar]
  • 9.Callaham M, Wears RL, Weber E. Journal prestige, publication bias, and other characteristics associated with citation of published studies in peer-reviewed journals. JAMA 2002;287:2847–50. 10.1001/jama.287.21.2847 [DOI] [PubMed] [Google Scholar]
  • 10.Garfield E, Welljams-Dorof A. Of Nobel class: a citation perspective on high impact research authors. Theor Med 1992;13:117–35. 10.1007/BF02163625 [DOI] [PubMed] [Google Scholar]
  • 11.Shuaib W, Khan MS, Shahid H et al. . Bibliometric analysis of the top 100 cited cardiovascular articles. Am J Cardiol 2015;115:972–81. 10.1016/j.amjcard.2015.01.029 [DOI] [PubMed] [Google Scholar]
  • 12.O'Sullivan KE, Kelly JC, Hurley JP. The 100 most cited publications in cardiac surgery: a bibliometric analysis. Ir J Med Sci 2015;184:91–9. 10.1007/s11845-014-1193-1 [DOI] [PubMed] [Google Scholar]
  • 13.Cassar Gheiti AJ, Downey RE, Byrne DP et al. . The 25 most cited articles in arthroscopic orthopaedic surgery. Arthroscopy 2012;28:548–64. 10.1016/j.arthro.2011.08.312 [DOI] [PubMed] [Google Scholar]
  • 14.Tam WW, Wong EL, Wong FC et al. . Citation classics: top 50 cited articles in ‘respiratory system’. Respirology 2013;18:71–81. 10.1111/j.1440-1843.2012.02262.x [DOI] [PubMed] [Google Scholar]
  • 15.Stern RS, Arndt KA. Top cited authors in dermatology: a citation study from 24 journals: 1982–1996. Arch Dermatol 1999;135:299–302. 10.1001/archderm.135.3.299 [DOI] [PubMed] [Google Scholar]
  • 16.Azer SA. The top-cited articles in medical education: a bibliometric analysis. Acad Med 2015;90:1147–61. 10.1097/ACM.0000000000000780 [DOI] [PubMed] [Google Scholar]
  • 17.Hung WT, Lee TC, Ying CC. Top 100 cited article in gastroenterology and hepatology: bird-view of research theme and trend over time by bibliometric study. J Gastroenterol Hepatol 2009;24:A35. [Google Scholar]
  • 18.Van Noorden R, Maher B, Nuzzo R. The top 100 papers. Nature 2014;514:550–3. 10.1038/514550a [DOI] [PubMed] [Google Scholar]
  • 19.Kulkarni AV, Aziz B, Shams I et al. . Comparisons of citations in Web of Science, Scopus, and Google Scholar for articles published in general medical journals. JAMA 2009;302:1092–6. 10.1001/jama.2009.1307 [DOI] [PubMed] [Google Scholar]
  • 20.Iñigo J, García-Samaniego J. Bibliometric analysis of publications in Gastroenterology and Hepatology in Spain from 2000 to 2009. Gastroenterol Hepatol 2012;35:551–9. 10.1016/j.gastrohep.2012.04.003 [DOI] [PubMed] [Google Scholar]
  • 21.Lefaivre KA, Guy P, O'Brien PJ et al. . Leading 20 at 20: top cited articles and authors in the Journal of Orthopaedic Trauma, 1987–2007. J Orthop Trauma 2010;24:53–8. 10.1097/BOT.0b013e3181aa2182 [DOI] [PubMed] [Google Scholar]
  • 22.Chiu WT, Ho YS. Bibliometric analysis of homeopathy research during the period of 1991 to 2003. Scientometrics 2005;63:3–23. 10.1007/s11192-005-0201-7 [DOI] [Google Scholar]
  • 23.Li Z, Ho YS. Use of citation per publication as an indicator to evaluate contingent valuation research. Scientometric 2008;75:97–110. 10.1007/s11192-007-1838-1 [DOI] [Google Scholar]
  • 24.Nawa RK, Lettvin C, Winkelman C et al. . Initial interrater reliability for a novel measure of patient mobility in a cardiovascular intensive care unit. J Crit Care 2014;29:475.e1–5. 10.1016/j.jcrc.2014.01.019 [DOI] [PubMed] [Google Scholar]
  • 25.Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–36. 10.1002/hep.20933 [DOI] [PubMed] [Google Scholar]
  • 26.Knodell RG, Ishak KG, Black WC et al. . Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431–5. 10.1002/hep.1840010511 [DOI] [PubMed] [Google Scholar]
  • 27.Ishak K, Baptista A, Bianchi L et al. . Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9. 10.1016/0168-8278(95)80226-6 [DOI] [PubMed] [Google Scholar]
  • 28.Bruix J, Sherman M, Llovet JM et al. . EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–30. 10.1016/S0168-8278(01)00130-1 [DOI] [PubMed] [Google Scholar]
  • 29.Best WR, Becktel JM, Singleton JW et al. . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439–44. [PubMed] [Google Scholar]
  • 30.Kleiner DE, Brunt EM, Van Natta M et al. . Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–21. 10.1002/hep.20701 [DOI] [PubMed] [Google Scholar]
  • 31.Desmet VJ, Gerber M, Hoofnagle JH et al. . Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–20. 10.1002/hep.1840190629 [DOI] [PubMed] [Google Scholar]
  • 32.El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557–76. 10.1053/j.gastro.2007.04.061 [DOI] [PubMed] [Google Scholar]
  • 33.Eberhart CE, Coffey RJ, Radhika A et al. . Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183–8. [DOI] [PubMed] [Google Scholar]
  • 34.Kamath PS, Wiesner RH, Malinchoc M et al. . A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–70. 10.1053/jhep.2001.22172 [DOI] [PubMed] [Google Scholar]
  • 35.Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998;114:842–5. 10.1016/S0016-5085(98)70599-2 [DOI] [PubMed] [Google Scholar]
  • 36.Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93. 10.1002/hep.510240201 [DOI] [PubMed] [Google Scholar]
  • 37.Robert A, Nezamis JE, Lancaster C et al. . Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 1979;77:433–43. [PubMed] [Google Scholar]
  • 38.Brunt EM, Janney CG, Di Bisceglie AM et al. . Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467–74. 10.1111/j.1572-0241.1999.01377.x [DOI] [PubMed] [Google Scholar]
  • 39.Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2. 10.1002/hep.24199 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Longstreth GF, Thompson WG, Chey WD et al. . Functional bowel disorders. Gastroenterology 2006;130:1480–91. 10.1053/j.gastro.2005.11.061 [DOI] [PubMed] [Google Scholar]
  • 41.Ghany MG, Strader DB, Thomas DL et al. . American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–74. 10.1002/hep.22759 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Matteoni CA, Younossi ZM, Gramlich T et al. . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–19. 10.1016/S0016-5085(99)70506-8 [DOI] [PubMed] [Google Scholar]
  • 43.Cotton PB, Lehman G, Vennes J et al. . Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383–93. 10.1016/S0016-5107(91)70740-2 [DOI] [PubMed] [Google Scholar]
  • 44.Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507–39. 10.1002/hep.21513 [DOI] [PubMed] [Google Scholar]
  • 45.Shay H, Komarov SA, Fels SS et al. . A simple method for the uniform production of gastric ulceration in the rat. Gastroenterology 1945;5:43–61. [Google Scholar]
  • 46.Flocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182–205. 10.1016/S0016-5085(98)70381-6 [DOI] [PubMed] [Google Scholar]
  • 47.Winawer SJ, Fletcher RH, Miller L et al. . Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594–642. 10.1053/gast.1997.v112.agast970594 [DOI] [PubMed] [Google Scholar]
  • 48.Browning JD, Szczepaniak LS, Dobbins R et al. . Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–95. 10.1002/hep.20466 [DOI] [PubMed] [Google Scholar]
  • 49.Vasen HF, Mecklin JP, Khan PM et al. . The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34: 424–5. 10.1007/BF02053699 [DOI] [PubMed] [Google Scholar]
  • 50.Winawer S, Fletcher R, Rex D et al. . Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology 2003;124:544–60. 10.1053/gast.2003.50044 [DOI] [PubMed] [Google Scholar]
  • 51.Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989;96:736–49. [PubMed] [Google Scholar]
  • 52.Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429–42. 10.1053/jhep.2003.50047 [DOI] [PubMed] [Google Scholar]
  • 53.Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (‘celiac sprue’). Gastroenterology 1992;102:330–54. [PubMed] [Google Scholar]
  • 54.Meng F, Henson R, Wehbe-Janek H et al. . MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133: 647–58. 10.1053/j.gastro.2007.05.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Vasen HF, Watson P, Mecklin JP et al. . New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453–6. 10.1016/S0016-5085(99)70510-X [DOI] [PubMed] [Google Scholar]
  • 56.Drossman DA, Li Z, Andruzzi E et al. . US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569–80. 10.1007/BF01303162 [DOI] [PubMed] [Google Scholar]
  • 57.Locke GR III, Talley NJ, Fett SL et al. . Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448–56. 10.1016/S0016-5085(97)70025-8 [DOI] [PubMed] [Google Scholar]
  • 58.Wai CT, Greenson JK, Fontana RJ et al. . A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26. 10.1053/jhep.2003.50346 [DOI] [PubMed] [Google Scholar]
  • 59.Strader DB, Wright T, Thomas DL et al. . American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147–71. 10.1002/hep.20119 [DOI] [PubMed] [Google Scholar]
  • 60.Morris GP, Beck PL, Herridge MS et al. . Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795–803. [PubMed] [Google Scholar]
  • 61.Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984;87:1344–50. [PubMed] [Google Scholar]
  • 62.Marchesini G, Bugianesi E, Forlani G et al. . Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–23. 10.1053/jhep.2003.50161 [DOI] [PubMed] [Google Scholar]
  • 63.Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–38. 10.1055/s-2007-1007122 [DOI] [PubMed] [Google Scholar]
  • 64.Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97–107. 10.1046/j.1365-2893.2003.00487.x [DOI] [PubMed] [Google Scholar]
  • 65.Granger DN, Rutili G, McCord JM. Superoxide radicals in feline intestinal ischemia. Gastroenterology 1981;81:22–9. [PubMed] [Google Scholar]
  • 66.Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661–2. 10.1002/hep.23190 [DOI] [PubMed] [Google Scholar]
  • 67.Loftus EV., Jr Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504–17. 10.1053/j.gastro.2004.01.063 [DOI] [PubMed] [Google Scholar]
  • 68.Okayasu I, Hatakeyama S, Yamada M et al. . A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694–702. [DOI] [PubMed] [Google Scholar]
  • 69.Vakil N, van Zanten SV, Kahrilas P et al. . Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900–20; quiz 1943 10.1111/j.1572-0241.2006.00630.x [DOI] [PubMed] [Google Scholar]
  • 70.Malfertheiner P, Megraud F, O'Morain C et al. . Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772–81. 10.1136/gut.2006.101634 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.O'Grady JG, Alexander GJ, Hayllar KM et al. . Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439–45. [DOI] [PubMed] [Google Scholar]
  • 72.Lo CM, Ngan H, Tso WK et al. . Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–71. 10.1053/jhep.2002.33156 [DOI] [PubMed] [Google Scholar]
  • 73.Castéra L, Vergniol J, Foucher J et al. . Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343–50. 10.1053/j.gastro.2004.11.018 [DOI] [PubMed] [Google Scholar]
  • 74.Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979;77(4 Pt 1):761–7. [PubMed] [Google Scholar]
  • 75.Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–35. 10.1136/gut.48.4.526 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Bosch FX, Ribes J, Díaz M et al. . Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5–16. 10.1053/j.gastro.2004.09.011 [DOI] [PubMed] [Google Scholar]
  • 77.Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131–57. 10.1053/j.gastro.2007.03.054 [DOI] [PubMed] [Google Scholar]
  • 78.Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449–57. 10.1016/j.hep.2003.09.022 [DOI] [PubMed] [Google Scholar]
  • 79.Hurwitz H, Fehrenbacher L, Novotny W et al. . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42. 10.1056/NEJMoa032691 [DOI] [PubMed] [Google Scholar]
  • 80.Choo QL, Kuo G, Weiner AJ et al. . Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359–62. 10.1126/science.2523562 [DOI] [PubMed] [Google Scholar]
  • 81.Pugh RN, Murray-Lyon IM, Dawson JL et al. . Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–9. 10.1002/bjs.1800600817 [DOI] [PubMed] [Google Scholar]
  • 82.Manns MP, McHutchison JG, Gordon SC et al. . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65. 10.1016/S0140-6736(01)06102-5 [DOI] [PubMed] [Google Scholar]
  • 83.Fried MW, Shiffman ML, Reddy KR et al. . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82. 10.1056/NEJMoa020047 [DOI] [PubMed] [Google Scholar]
  • 84.Llovet JM, Ricci S, Mazzaferro V et al. . SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90. 10.1056/NEJMoa0708857 [DOI] [PubMed] [Google Scholar]
  • 85.Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159–70. 10.1016/S0092-8674(00)81333-1 [DOI] [PubMed] [Google Scholar]
  • 86.Perna NT, Plunkett G III, Burland V et al. . Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature 2001;409:529–33. 10.1038/35054089 [DOI] [PubMed] [Google Scholar]
  • 87.Hugot JP, Chamaillard M, Zouali H et al. . Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599–603. 10.1038/35079107 [DOI] [PubMed] [Google Scholar]
  • 88.Tomb JF, White O, Kerlavage AR et al. . The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997;388:539–47. 10.1038/41483 [DOI] [PubMed] [Google Scholar]
  • 89.Mazzaferro V, Regalia E, Doci R et al. . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–9. 10.1056/NEJM199603143341104 [DOI] [PubMed] [Google Scholar]
  • 90.Kuo G, Choo QL, Alter HJ et al. . An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362–4. 10.1126/science.2496467 [DOI] [PubMed] [Google Scholar]
  • 91.Ogura Y, Bonen DK, Inohara N et al. . A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603–6. 10.1038/35079114 [DOI] [PubMed] [Google Scholar]
  • 92.Parsonnet J, Friedman GD, Vandersteen DP et al. . Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127–31. 10.1056/NEJM199110173251603 [DOI] [PubMed] [Google Scholar]
  • 93.Dixon MF, Genta RM, Yardley JH et al. . Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–81. 10.1097/00000478-199610000-00001 [DOI] [PubMed] [Google Scholar]
  • 94.Burris HA III, Moore MJ, Andersen J et al. . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–13. [DOI] [PubMed] [Google Scholar]
  • 95.Cunningham D, Humblet Y, Siena S et al. . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45. 10.1056/NEJMoa033025 [DOI] [PubMed] [Google Scholar]
  • 96.Hayashi T, Makino K, Ohnishi M et al. . Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res 2001;8:11–22. 10.1093/dnares/8.1.11 [DOI] [PubMed] [Google Scholar]
  • 97.Feder JN, Gnirke A, Thomas W et al. . A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399–408. 10.1038/ng0896-399 [DOI] [PubMed] [Google Scholar]
  • 98.McHutchison JG, Gordon SC, Schiff ER et al. . Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485–92. 10.1056/NEJM199811193392101 [DOI] [PubMed] [Google Scholar]
  • 99.Groux H, O'Garra A, Bigler M et al. . A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737–42. 10.1038/39614 [DOI] [PubMed] [Google Scholar]
  • 100.Morin PJ, Sparks AB, Korinek V et al. . Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787–90. 10.1126/science.275.5307.1787 [DOI] [PubMed] [Google Scholar]
  • 101.Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998;11:142–201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Boland CR, Thibodeau SN, Hamilton SR et al. . A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248–57. [PubMed] [Google Scholar]
  • 103.Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–17. 10.1016/S0140-6736(03)14964-1 [DOI] [PubMed] [Google Scholar]
  • 104.Demetri GD, von Mehren M, Blanke CD et al. . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80. 10.1056/NEJMoa020461 [DOI] [PubMed] [Google Scholar]
  • 105.Winawer SJ, Zauber AG, Ho MN et al. . Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977–81. 10.1056/NEJM199312303292701 [DOI] [PubMed] [Google Scholar]
  • 106.Aaltonen LA, Peltomäki P, Leach FS et al. . Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812–16. 10.1126/science.8484121 [DOI] [PubMed] [Google Scholar]
  • 107.Bombardier C, Laine L, Reicin A et al. . VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520–8. 10.1056/NEJM200011233432103 [DOI] [PubMed] [Google Scholar]
  • 108.Thiebaut F, Tsuruo T, Hamada H et al. . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735–8. 10.1073/pnas.84.21.7735 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Fishel R, Lescoe MK, Rao MR et al. . The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027–38. 10.1016/0092-8674(93)90546-3 [DOI] [PubMed] [Google Scholar]
  • 110.Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221–31. 10.1056/NEJMra011775 [DOI] [PubMed] [Google Scholar]
  • 111.Targan SR, Hanauer SB, van Deventer SJ et al. . A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029–35. 10.1056/NEJM199710093371502 [DOI] [PubMed] [Google Scholar]
  • 112.Stocker R, Yamamoto Y, McDonagh AF et al. . Bilirubin is an antioxidant of possible physiological importance. Science 1987;235:1043–6. 10.1126/science.3029864 [DOI] [PubMed] [Google Scholar]
  • 113.Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417–29. 10.1056/NEJMra020831 [DOI] [PubMed] [Google Scholar]
  • 114.de Gramont A, Figer A, Seymour M et al. . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–47. [DOI] [PubMed] [Google Scholar]
  • 115.Hadziyannis SJ, Sette H Jr, Morgan TR et al. . PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55. 10.7326/0003-4819-140-5-200403020-00010 [DOI] [PubMed] [Google Scholar]
  • 116.Mandel JS, Bond JH, Church TR et al. . Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365–71. 10.1056/NEJM199305133281901 [DOI] [PubMed] [Google Scholar]
  • 117.Saltz LB, Cox JV, Blanke C et al. . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–14. 10.1056/NEJM200009283431302 [DOI] [PubMed] [Google Scholar]
  • 118.Uemura N, Okamoto S, Yamamoto S et al. . Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–9. 10.1056/NEJMoa001999 [DOI] [PubMed] [Google Scholar]
  • 119.Beasley RP, Hwang LY, Lin CC et al. . Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129–33. 10.1016/S0140-6736(81)90585-7 [DOI] [PubMed] [Google Scholar]
  • 120.Koh HK. “Viral Hepatitis: The Secret Epidemic.” Testimony before the Committee on Oversight and Governmental Reform, United States House of Representatives, 17 June 2010 http://www.hhs.gov/asl/testify/2010/06/t20100617b.html (accessed 23 Jan 2016).
  • 121.Institute of Medicine (IOM). Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington DC: The National Academies Press, 2010:1–232. [PubMed] [Google Scholar]
  • 122.Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015;12:205–17. 10.1038/nrgastro.2015.34 [DOI] [PubMed] [Google Scholar]
  • 123.Edwards BK, Noone AM, Mariotto AB et al. . Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014;120:1290–314. 10.1002/cncr.28509 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Loonen MP, Hage JJ, Kon M. Plastic Surgery Classics: characteristics of 50 top-cited articles in four Plastic Surgery Journals since 1946. Plast Reconstr Surg 2008;121:320e–7e. 10.1097/PRS.0b013e31816b13a9 [DOI] [PubMed] [Google Scholar]
  • 125.Lowry OH, Rosebrough NJ, Farr AL et al. . Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–75. [PubMed] [Google Scholar]
  • 126.Danthi N, Wu CO, Shi P et al. . Percentile ranking and citation impact of a large cohort of National Heart, Lung, and Blood Institute-funded cardiovascular R01 grants. Circ Res 2014;114:600–6. 10.1161/CIRCRESAHA.114.302656 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Fortin JM, Currie DJ. Big Science vs. Little Science: How Scientific Impact Scales with Funding. PLoS ONE 2013;8:e65263 10.1371/journal.pone.0065263 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Long MT, Leszczynski A, Thompson KD et al. . Female authorship in major academic gastroenterology journals: a look over 20 years. Gastrointest Endosc 2015;81:1440–7.e3. 10.1016/j.gie.2015.01.032 [DOI] [PubMed] [Google Scholar]
  • 129.Tang X, Gong W, Yuan F et al. . Top-cited articles in digestive system disease from 1950 to 2013. J Gastroenterol Hepatol 2016;31:107–11. [DOI] [PubMed] [Google Scholar]

Articles from BMJ Open are provided here courtesy of BMJ Publishing Group

RESOURCES